The proposed new guidelines for Special Pricing Arrangements say they will be in place until a medicine moves to F2 or for a "maximum" of three years. …
Latest Video
New Stories
-
Potential merger could create a new global oncology powerhouse
August 3, 2026 - - Latest News -
First new brain cancer treatment listed on PBS after more than 20 years
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News -
Listing offers treatment option for Australians with tumour induced osteomalacia
August 3, 2026 - - Latest News -
Funding for new chemotherapy-free immunotherapy combination for follicular lymphoma
August 3, 2026 - - Latest News -
The 'Dispatched' Week in Review' Podcast - 31 July
July 31, 2026 - - Podcast -
New partnership aims to create national blueprint for earlier Alzheimer’s diagnosis and care
July 31, 2026 - - Latest News